๐๐๐ฏ๐๐ซ๐ฎ๐ฆโ๐ฌ ๐๐๐ง๐ ๐๐ก๐๐ซ๐๐ฉ๐ฒ ๐๐จ๐ซ ๐๐๐ญ ๐๐๐ ๐๐๐ซ๐ง๐ฌ ๐
๐๐โ๐ฌ ๐๐๐๐ ๐๐๐ฌ๐ข๐ ๐ง๐๐ญ๐ข๐จ๐ง.
๐ Adverum Biotechnologies has received the FDAโs Regenerative Medicine Advanced Therapy (RMAT) designation for its gene therapy, lxoberogene soroparvovec (Ixo-vec), aimed at treating wet age-related macular degeneration (AMD). This designation is based on promising early clinical data and could expedite the therapyโs development. Ixo-vec, which uses Adverumโs proprietary AAV.7m8 vector technology, has already shown potential in reducing treatment burden and maintaining vision. The company plans to continue its collaboration with regulators, with updates expected later this year.